Real-world application of nirmatrelvir/ritonavir in hospitalized COVID-19 patients with onset of symptoms beyond 5  days: a comparative study

ConclusionsThe application of Nirmatrelvir-ritonavir was associated with a significantly reduced risk of intubation or death in hospitalized COVID-19 patients who experienced symptoms for more than 5  days as compared to those who did not receive the treatment.
Source: Infection - Category: Infectious Diseases Source Type: research